NEW YORK (GenomeWeb) – GeneCentric Diagnostics said in a document filed with the US Securities and Exchange Commission on Friday that it has raised $5 million in equity.

In an email to GenomeWeb Daily News, GeneCentric CEO Myla Lai-Goldman said the financing is the closing of the second tranche of the company's Series A financing round, and proceeds will go toward the continued development of its lead product called the Lung Subtype Platform. The company has raised $5.25 million to date, she said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.